About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Texas | 1,133 Studies

Clinical Trials LymphomaTexas

Lymphoma Clinical Trials in Texas

Find 1,133 clinical trials for lymphoma near Texas. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Texas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 1101-1120 of 1,133 trials

TerminatedPhase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaThe purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC.NCT02110563·Stanford, California and 5 others TerminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasThe primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated…NCT01732913·Huntsville, Alabama and 102 others

PreviousPage 56 of 57Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedAutologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell…NCT00096460·Duarte, California and 29 others

CompletedStudy of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsTo determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer.NCT00562224·Greenbrae, California and 3 others

RecruitingA Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLTo learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.NCT05615636·Houston, Texas

Active not recruitingTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLPart 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL…NCT06072131·Clovis, California and 57 others

CompletedCollecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaThis research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma.NCT01000753·Birmingham, Alabama and 129 others

RecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLThis is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or…NCT06500273·Gilbert, Arizona and 85 others

CompletedStudy To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisStudy B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize…NCT02780167·Birmingham, Alabama and 63 others

TerminatedA Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaThis study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts.NCT04074330·Birmingham, Alabama and 58 others

UnknownPixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseRATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop…NCT00069966·Tucson, Arizona and 28 others

CompletedSafety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisTo assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or…NCT02093663·Baltimore, Maryland and 32 others

CompletedPhase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaThe primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or…NCT01939899·Boston, Massachusetts and 13 others

TerminatedPhase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or…NCT04745832·Tucson, Arizona and 140 others

CompletedFirst-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasThe ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.NCT03188965·Duarte, California and 28 others

CompletedInvestigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)RATIONALE: BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.NCT00243087·Washington D.C., District of Columbia and 3 others

CompletedA Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaThis is a Phase I, multicenter, open-label, dose-escalation study of polatuzumab vedotin administered as a single agent by intravenous (IV) infusion to participants with relapsed…NCT01290549·Stanford, California and 15 others

CompletedStudy of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's DiseaseThis Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's…NCT00364676·San Antonio, Texas and 2 others

RecruitingA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLThe goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.NCT04496349·Houston, Texas

CompletedEscalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaThe purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic…NCT01351935·Huntsville, Alabama and 12 others

Other Conditions in Texas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia